Cyclotherapy: opening a therapeutic window in cancer treatment

Ingeborg M.M. van Leeuwen

doi:10.18632/oncotarget.524

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Cyclotherapy: opening a therapeutic window in cancer treatment

Ingeborg M.M. van Leeuwen _

PDF | HTML | How to cite

Oncotarget. 2012; 3:596-600. https://doi.org/10.18632/oncotarget.524

Metrics: PDF 3032 views | HTML 3572 views | ?

Abstract

Ingeborg M.M. van Leeuwen1

1 Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Correspondence:

Ingeborg M.M. van Leeuwen, email:

Keywords: Cyclotherapy, chemotherapy, p53, nutlin-3, tenovin-6, leptomycin B, actinomycin D

Received: May 18, 2012, Accepted: June 15, 2012, Published: June 16, 2012

Abstract

Cyclotherapy is a promising endeavor to improve cancer treatment by tackling the dose-limiting side effects of chemotherapy, especially for cancers harboring mutations in the TP53 tumor suppressor. In this particular context, pre-treatment with a p53 activator halts proliferation in healthy tissue, while leaving the p53-deficient tumor susceptible to conventional chemotherapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 524

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Cyclotherapy: opening a therapeutic window in cancer treatment

Abstract